Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Breast Cancer Res Treat. 2015 Apr 28;151(2):415–425. doi: 10.1007/s10549-015-3391-6

PREMENOPAUSAL PLASMA CAROTENOIDS, FLUORESCENT OXIDATION PRODUCTS AND SUBSEQUENT BREAST CANCER RISK IN THE NURSES’ HEALTH STUDIES

JULIA S SISTI 1, SARA LINDSTRÖM 1,4, PETER KRAFT 1,2,4, RULLA M TAMIMI 1,5, BERNARD A ROSNER 2,5, TIANYING WU 6, WALTER C WILLETT 1,3,5, A HEATHER ELIASSEN 1,5
PMCID: PMC4437794  NIHMSID: NIHMS685186  PMID: 25917867

Abstract

Purpose

High levels of circulating carotenoids are hypothesized to reduce breast cancer risk, potentially due to their antioxidant properties. However, little is known about the relationship between carotenoid exposure earlier in life and risk.

Methods

We examined associations of premenopausal plasma carotenoids and markers of oxidative stress and risk of breast cancer among 1,179 case-control pairs in the Nurses’ Health Study (NHS) and NHSII. Levels of α- and β-carotene, β-cryptoxanthin, lycopene and lutein/zeaxanthin were quantified by high-performance liquid chromatography. Three fluorescent oxidation products (FlOP_360, FlOP_320, FlOP_400) were measured in a subset of participants by spectrofluoroscopy. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for breast cancer by quartile, as well as P-values for tests of linear trend. We additionally examined whether 45 single nucleotide polymorphisms (SNPs) in five genes involved in oxidative and antioxidative processes or carotenoid availability were associated with risk.

Results

Carotenoid measures were not inversely associated with breast cancer risk. No differences by estrogen receptor status were observed, though some inverse associations were observed among women postmenopausal at diagnosis. Plasma FlOP levels were not positively associated with risk, and suggestive inverse associations with FlOP_320 and FlOP_360 were observed. Several SNPs were associated with carotenoid levels, and a small number were suggestively associated with breast cancer risk. We observed evidence of interactions between some SNPs and carotenoid levels on risk.

Conclusion

We did not observe consistent associations between circulating levels of premenopausal carotenoids or FlOP levels and breast cancer risk.

Keywords: breast cancer, fluorescent oxidation products, carotenoids, oxidative stress

INTRODUCTION

The role of dietary factors in breast cancer etiology has attracted substantial interest. Specifically, diets rich in fruits and vegetables have been hypothesized to reduce cancer risk, though results from several large-scale epidemiologic studies of breast cancer have been inconclusive.15 Despite these equivocal findings, it remains biologically plausible that some components of fruits and vegetables have anti-carcinogenic effects. One class of compounds that has attracted considerable interest is carotenoids, fat-soluble nutrients responsible for the coloring of many red, orange, and dark green fruits and vegetables. Some epidemiologic studies of carotenoids and breast cancer risk have suggested a modest protective effect of at least some carotenoids, with stronger results typically seen in studies examining circulating biomarkers than those relying on measures derived from recalled dietary data.616 Most recently, our pooled analysis (n=3,055 cases) reported significant inverse associations between circulating α-carotene, β-carotene, lycopene, lutein/zeaxanthin and total carotenoids levels and breast cancer risk, with relative risks (RRs) (top vs. bottom quintiles) of 0.78–0.87.17 The associations with carotenoids may vary by breast cancer subtype, with a stronger protective effect observed for estrogen receptor negative (ER−), compared to estrogen receptor positive (ER+) tumors.17,18

The potential mechanisms through which carotenoids may influence breast cancer risk are numerous. Carotenoids may promote cellular differentiation and inhibit tumorigenesis and proliferation, either directly or through the conversion of the provitamin A carotenoids (α-carotene, β-carotene and β-cryptoxanthin) to retinol. Further, carotenoids may act via their antioxidant properties. At high levels, reactive oxygen species (ROS) produced by endogenous and exogenous processes may induce potentially carcinogenic DNA damage and gene expression modification.18 Antioxidants, including carotenoids and several endogenous enzymes, may inhibit carcinogenesis by neutralizing these reactive molecules, thereby reducing the burden of oxidative stress. To date, largely null results have been reported from a small number of prospective studies of various oxidative stress biomarkers and breast cancer risk.19,20 including our analysis in the Nurses’ Health Study (NHS),21 which examined plasma levels of three fluorescent oxidation products (FlOP_360, FlOP_320, FlOP_400). Thus, the roles of oxidative stress and antioxidant activity in breast cancer etiology are not clear.

Presently, little is known about the relationship between carotenoid exposure earlier in life and breast cancer risk. In our pooled analysis,17 which included data from nearly all published prospective studies of circulating carotenoids and breast cancer, 67% of participants were postmenopausal when biomarkers were measured. Here, we examined the relationship between premenopausal plasma carotenoid and fluorescent oxidation products levels and subsequent breast cancer risk in the NHS and NHSII. To maximize power, we included premenopausal women from previously published data sets in the NHS.10,21 We also explored interactions between carotenoids and several single-nucleotide polymorphisms (SNPs) in genes hypothesized to predict carotenoid availability or influence ROS formation and neutralization among NHSII participants.

METHODS

Study population

The NHS and NHSII are ongoing prospective cohorts, initiated in 1976 and 1989, respectively. The NHS was established among 121,700 registered female nurses, ages 30–55 years; the NHSII was established among 116,430 registered female nurses, ages 25–42 years. At baseline, and on subsequent biennial questionnaires, participants provided updated information about lifestyle factors and medical diagnoses.

Biospecimen collection

In 1989–1990, 32,826 NHS participants, ages 43–70 years, provided blood samples and responded to a short questionnaire.22 Participants had their blood drawn and samples were returned to the laboratory, with an icepack, via overnight courier, with 97% arriving within 26 hours of blood draw. Upon arrival, blood samples were centrifuged to isolate plasma, buffy coat, and red blood cell components.

The NHSII blood collection occurred in 1996–99, when 29,611 participants who were cancer-free and ages 32–54 years provided blood samples and answered a short questionnaire.23 Of these women, 18,521 who were premenopausal and had not been pregnant, breastfed, or used oral contraceptives in the 6 months preceding collection provided samples timed within their menstrual cycle. Participants collected follicular phase blood samples during days 3–5 of their menstrual cycle, and blood and urine samples during the luteal phase, 7–9 days before the anticipated start of their next cycle. Participants were instructed to separate follicular phase via pipette and freeze the plasma component before returning it to the laboratory. Samples were stored with an ice pack and returned to the laboratory via overnight courier; 93% of samples were received within 26 hours of collection. Upon arrival at the laboratory, luteal phase samples were processed similarly to NHS samples. Blood samples from both cohorts were aliquoted into cryotubes and stored in liquid nitrogen freezers.

NHS case-control selection

Eligible breast cancer cases who were premenopausal at blood draw and diagnosed before June 1, 2010 were selected from a previous analysis of carotenoids and breast cancer risk.17,24 A total of 498 cases were reported on biennial questionnaires and subsequently confirmed through medical record review (n=495) or verbal confirmation (n=3). Cases were matched (1:1) to controls age (±2 years), month (±1) and time of day of blood draw (±2 hours), fasting status (<2, 2–4, 5–7, 8–11, 12+ hours), and menopausal status at blood draw and diagnosis. A total of 466 pairs were included in carotenoid analyses. FlOP assays were performed for cases diagnosed before June 1, 2006 (383 pairs).

NHSII case-control selection

Breast cancer cases were participants premenopausal at blood collection and diagnosed before June 1, 2011. Cases were matched to controls on age (±2 years), race, menopausal status at blood draw and diagnosis, luteal day (±1 day for timed samples), month (±2), time of day (±2 hours), and fasting status (<2, 2–4, 5–7, 8–11, 12+ hours) of blood draw. Plasma biomarker analyses used one matched case per control. The carotenoids analyses include a total of 677 pairs. FlOP assays were conducted on cases diagnosed prior to June 1, 2007 (401 pairs). For genetic analyses, cases were diagnosed before June 1, 2009, and matched to controls in either a 1:1 or 1:2 frequency (613 cases, 1066 controls). Genetic analyses were restricted to Caucasian participants to reduce the possibility of population stratification.

Laboratory methods

Case-control pairs were assayed together in random order by technicians blinded to case status. Plasma carotenoids were assayed at the Micronutrient Analysis Laboratory at the Harvard School of Public Health Department of Nutrition using the reversed-phase, high-performance liquid chromatography method previously described by El-Sohemy et al.25 Levels of α-carotene, β-carotene, β-cryptoxanthin, lutein/zeaxanthin and lycopene were assessed, and summed to calculate total carotenoids. Carotenoids were assayed in 11 batches (9 in NHS; 2 in NHSII); coefficients of variation (CVs) were ≤15%, with the exception of three batches of α-carotene, two batches of β-carotene and 1 batch each of β-cryptoxanthin and lycopene, which each had CVs of ≤20%; 1 batch of β-cryptoxanthin had CV=22%.

FlOP levels were assayed at the University of Cincinnati using a spectrofluoroscopy method previously described by Wu et al.26 Concentrations of three individual FlOPs were assessed: FlOP_360 (excitation 360 nm, emission 420 nm), FlOP_320 (excitation 320 nm, emission 420 nm), and FlOP_400 (excitation 400 nm, emission 475 nm). FlOPs were assayed in 3 batches (2 in NHS; 1 in NHSII); CVs for all FlOP measures were ≤20%.

Evidence of batch-to-batch variability in biomarker assays was observed; therefore, NHScarotenoid measurements were recalibrated using replicates of participant samples.17 FlOP measurements from both cohorts were recalibrated to an average batch using methods previously described by Rosner et al.21,27 The number of participants included in analyses varies by biomarker due to laboratory difficulties that resulted in missing values for some participants.

SNP selection and genotyping

The Tagger algorithm28 in the Haploview program29 and dense genotyping data from the HapMap Release 28 CEU panel was used to select a total of 45 SNPs in five genes (CAT, GPX1, SOD2, MPO, BCMO1) that were of interest due to their biologic roles in oxidative and antioxidative processes.30,31 SNPs were selected to capture variation with a coefficient of determination (R2) >0.8 in a segment spanning 20 kb upstream and 10 kb downstream of each gene. We selected tagging SNPs with a minor allele frequency >5% in the reference panel, including the two candidate SNPs rs1050450 and rs4880, in GPX1 and SOD2, respectively. We included two additional BCMO1 SNPs, rs1641417 and rs7501331, that were previously genotyped in NHSII.32

Genotyping was performed at the Dana Farber/Harvard Cancer Center High Throughput Polymorphism Detection Core, with Taqman OpenArray SNP Genotyping Platform. All case-control pairs were processed in the same batch by technicians blinded to case status, and duplicate samples were included across batches as quality controls. Call rates for all SNPs were >97%.

Covariates

Covariate information was obtained from biennial questionnaires (height, age at menarche, parity, age at first birth, family history of breast cancer, history of benign breast disease) and blood collection questionnaires (weight, smoking status).

Statistical analyses

Statistical outliers in plasma biomarkers were identified and removed using the extreme Studentized deviate many-outlier procedure; 33 the number of outliers ranged from 2 (α-carotene) to 56 (FlOP_320). Quartile cutpoints were determined using distributions among the controls; results were similar when quintiles were examined. Linear tests for trend were conducted by modeling quartile medians continuously and evaluating the Wald statistic. We additionally cross-classified total carotenoid and individual FlOPs by dichotomizing each biomarker at its median.

We pooled NHS and NHSII data and used conditional logistic regression models adjusted for several breast cancer risk factors to estimate RRs and corresponding 95% confidence intervals (95% CI). To examine variation in associations across subgroups, we evaluated the significance of interaction terms between the ordinal median biomarker variable and binary variables for cohort, BMI, smoking status, and menopausal status at diagnosis using Wald tests. We used polytomous logistic regression34 to evaluate whether associations varied by ER status, which was determined by medical record review.

Tests for deviation from Hardy-Weinberg equilibrium were conducted among controls for all SNPs using the Pearson’s goodness of fit test with a cutoff of 0.01. For all genetic analyses, SNP effects were assumed to be additive, and the number of minor alleles was modeled as an ordinal variable (0, 1, 2).

Associations between SNPs and plasma carotenoid levels were evaluated among controls using age-adjusted generalized linear models. Tests for trend were conducted by modeling number of minor alleles continuously and calculating the Wald statistic. To examine associations between SNPs and breast cancer risk, per-allele RRs were estimated using age-adjusted unconditional logistic regression models. Interactions between SNPs and plasma carotenoid levels on risk were also evaluated using age-adjusted unconditional logistic regression. Plasma carotenoid levels were dichotomized at their medians, and per-allele RRs were calculated separately by carotenoid level. Likelihood ratio tests were used to calculate P-values for interaction terms that were the product of number of minor alleles and continuous carotenoid levels. All P-values were two-sided and tests of significance were performed at the α=0.05 level. All analyses were conducted using SAS v. 9.2 (SAS Institute, Cary, NC).

RESULTS

Overall, 1,143 matched case-control pairs across both cohorts had carotenoid data and 784 pairs had FlOP data; a total of 748 pairs had both carotenoid and FlOP data. Genotype data were available for 597 cases and 1,048 controls, of which 536 cases and 531 controls also had carotenoids measured. Among 1,179 cases and matched controls in the carotenoid or FlOP analyses, average age at blood draw was 46 years (NHS: 48 years; NHSII: 43 years) (Table 1). Cases and controls were similar with regard to most characteristics, though cases were more likely than controls to report a family history of breast cancer and a personal history of benign breast disease. 44% of cases were postmenopausal at diagnosis.

Table 1.

Characteristics of the premenopausal study population at blood draw, Nurses Health Study and Nurses Health Study IIa

NHS NHSII

Case (n=498) Control (n=498) Case (n=681) Control (n=681)
Age at blood draw, years 48.3 (3.2) 48.3 (3.2) 43.4 (4.0) 43.6 (3.9)
Age at menarche, years 12.3 (1.3) 12.5 (1.3) 12.4 (1.3) 12.5 (1.4)
BMI at age 18, kg/m2 21.1 (2.7) 21.3 (2.8) 20.8 (3.0) 21.0 (2.8)
Height, inches 64.7 (2.4) 64.6 (2.3) 65.3 (2.5) 64.8 (2.6)
BMI at blood draw, kg/m2 25.1 (4.3) 25.2 (4.9) 24.8 (4.8) 25.6 (5.4)
Weight change since age 18 10.6 (10.5) 10.5 (11.0) 10.9 (11.0) 12.2 (11.7)
Parity, children 2.6 (1.1) 2.6 (1.2) 1.7 (1.2) 2.0 (1.3)
Age at first birth, years 24.9 (2.9) 24.9 (2.8) 27.3 (4.6) 26.4 (4.5)
Physical activity, MET-hrs/wk 13.7 (22.3) 14.1 (16.8) 17.2 (19.7) 18.2 (23.1)
Alcohol consumption, g/d 4.3 (7.7) 4.5 (7.2) 3.9 (6.7) 3.2 (6.0)
History of benign breast disease, % 58 48 20 13
Family history of breast cancer, % 12 6 18 10
Median (IQR)
Median (IQR)
Alpha-carotene, ug/dL 7.1 (4.5–11) 7.2 (4.6–12) 7.0 (4.5–12) 7.2 (4.6–11)
Beta-carotene, ug/dL 23 (15–36) 23 (15–35) 24 (16–38) 23 (15–37)
Beta-cryptoxanthin, ug/dL 10 (7.3–15) 10 (7.6–14) 10 (7.0–14) 10 (7.1–14)
Lycopene, ug/dL 43 (32–53) 43 (33–55) 42 (32–53) 43 (34–55)
Lutein-zeaxanthin, ug/dL 22 (16–28) 21 (16–27) 17 (13–22) 17 (13–22)
Total carotenoids, ug/dL 108 (86–142) 110 (87–139) 107 (83–136) 107 (83–134)
FlOP_360, FI/mL 205 (170–247) 209 (178–252) 210 (173–250) 211 (175–252)
FlOP_320, FI/mL 313 (254–426) 335 (261–451) 338 (278–441) 345 (277–455)
FlOP_400, FI/mL 65 (55–78) 66 (56–79) 64 (53–78) 64 (52–78)
a

Values are means (SD) or percentages and are standardized to the age distribution of the study population; biomarker measures are not age-adjusted.

Individual carotenoids were significantly positively correlated with one another; Spearman correlations ranged from r=0.28 (α-carotene and lycopene) to 0.77 (α-carotene and β-carotene). Significant correlations also were observed among FlOP measures (FlOP_360 and FlOP_320, r=0.58; FlOP_360 and FlOP_400, r=0.73; FlOP_320 and FlOP_400, r=0.49). Weak, but significant, correlations ranging from r=0.10 (α-carotene) to 0.23 (lycopene) were observed between FlOP_360 and carotenoids; FlOP_320 and FlOP_360 were not correlated with carotenoids.

Plasma carotenoids were not inversely associated with breast cancer risk overall (Table 2) (e.g., total carotenoids top vs. bottom quartile RR=0.99, 95% CI (0.77–1.28), ptrend=0.67). Similarly, FLOP levels were not positively associated with risk (Table 3), though we observed some evidence of inverse associations with FlOP_360 (top vs. bottom quartile RR=0.68, 95% CI: 0.50, 0.95; ptrend=0.07) and FlOP_320 (RR=0.76, 95% CI: 0.55, 1.06; ptrend=0.08).

Table 2.

Relative risks (RR) of breast cancer and 95% confidence intervals (CI) according to quartile of premenopausal carotenoid levels (ug/dL)

RR RR 95% CI RR 95% CI RR 95% CI Ptrend
α-Carotene
Quartile Cutpoints <4.6 ≥4.6 to <7.2 ≥7.2 to <12 ≥12
Case/Control No. 298/285 286/284 263/283 286/281
Unadjusted RR (95% CI) 1.0 (reference) 0.96 (0.76, 1.21) 0.89 (0.70, 1.12) 0.97 (0.77, 1.23) 0.85
Multivariate RRa (95% CI) 1.0 (reference) 0.93 (0.73, 1.19) 0.85 (0.67, 1.09) 0.93 (0.73, 1.19) 0.62
β-Carotene
Quartile Cutpoints <15 ≥15 to <23 ≥23 to <36 ≥36
Case/Control No. 282/284 285/284 259/282 306/282
Unadjusted RR (95% CI) 1.0 (reference) 1.01 (0.80, 1.28) 0.92 (0.73, 1.17) 1.10 (0.87, 1.39) 0.44
Multivariate RRa (95% CI) 1.0 (reference) 0.97 (0.76, 1.23) 0.87 (0.68, 1.13) 0.99 (0.77, 1.28) 0.98
β-Cryptoxanthin
Quartile Cutpoints <7.3 ≥7.3 to <10 ≥10 to <14 ≥14
Case/Control No. 302/285 262/282 290/281 275/281
Unadjusted RR (95% CI) 1.0 (reference) 0.87 (0.69, 1.11) 0.97 (0.77, 1.23) 0.92 (0.73, 1.17) 0.72
Multivariate RRa (95% CI) 1.0 (reference) 0.82 (0.64, 1.05) 0.93 (0.72, 1.19) 0.83 (0.64, 1.07) 0.27
Lutein/Zeaxanthin
Quartile Cutpoints <14 ≥14 to <19 ≥19 to <24 ≥24
Case/Control No. 263/282 288/282 278/279 298/284
Unadjusted RR (95% CI) 1.0 (reference) 1.10 (0.87, 1.39) 1.07 (0.85, 1.36) 1.14 (0.89, 1.47) 0.36
Multivariate RRa (95% CI) 1.0 (reference) 1.06 (0.83, 1.35) 1.03 (0.80, 1.31) 1.02 (0.78, 1.34) 0.96
Lycopene
Quartile Cutpoints <33 ≥33 to <43 ≥43 to <55 ≥55
Case/Control No. 324/282 253/282 299/284 254/282
Unadjusted RR (95% CI) 1.0 (reference) 0.78 (0.62, 0.99) 0.91 (0.73, 1.15) 0.78 (0.61, 0.99) 0.10
Multivariate RRa (95% CI) 1.0 (reference) 0.81 (0.64, 1.04) 0.92 (0.72, 1.17) 0.80 (0.62, 1.02) 0.14
Total Carotenoids
Quartile Cutpoints <85 ≥85 to <109 ≥109 to <136 ≥136
Case/Control No. 279/283 297/276 247/278 288/274
Unadjusted RR (95% CI) 1.0 (reference) 1.09 (0.86, 1.39) 0.90 (0.70, 1.15) 1.07 (0.84, 1.36) 0.81
Multivariate RRa (95% CI) 1.0 (reference) 1.09 (0.85, 1.40) 0.86 (0.66, 1.11) 0.99 (0.77, 1.28) 0.67
a

Adjusted for BMI at blood draw (<25, 25-<25.9, ≥30 kg/m2), age at menarche (≤11, 12, 13, ≥14 years old), alcohol intake (non-drinker, ≤5, 5.01–10, 10.01–15, >15 grams/day), parity/age at first birth (nulliparous, 1 child/<25 years old, 1 child/≥25 years old, ≥2 children/<25 years old, ≥2 children/≥25 years old), family history of breast cancer (yes/no), history of benign breast disease (yes/no)

Table 3.

Relative risks (RR) of breast cancer and 95% confidence intervals (CI) according to quartile of premenopausal FlOP levels (FI/mL)

RR RR 95% CI RR 95% CI RR 95% CI Ptrend
FlOP_360
Quartile Cutpoints <176 ≥176 to <209 ≥209 to <252 ≥252
Case/Control No. 216/187 172/192 200/193 176/192
Unadjusted RR (95% CI) 1.0 (reference) 0.77 (0.57, 1.02) 0.90 (0.67, 1.20) 0.77 (0.57, 1.04) 0.21
Multivariate RRa (95% CI) 1.0 (reference) 0.71 (0.52, 0.96) 0.85 (0.63, 1.16) 0.68 (0.50, 0.95) 0.07
FlOP_320
Quartile Cutpoints <271 ≥271 to <339 ≥339 to <453 ≥453
Case/Control No. 193/179 200/184 172/180 161/183
Unadjusted RR (95% CI) 1.0 (reference) 0.99 (0.74, 1.33) 0.86 (0.62, 1.19) 0.80 (0.58, 1.09) 0.11
Multivariate RRa (95% CI) 1.0 (reference) 0.97 (0.71, 1.32) 0.83 (0.59, 1.16) 0.76 (0.55, 1.06) 0.08
FlOP_400
Quartile Cutpoints <53 ≥53 to <64 ≥64 to <79 ≥79
Case/Control No. 177/190 200/194 208/192 186/195
Unadjusted RR (95% CI) 1.0 (reference) 1.12 (0.83, 1.51) 1.17 (0.87, 1.58) 1.04 (0.77, 1.42) 0.96
Multivariate RRa (95% CI) 1.0 (reference) 1.14 (0.83, 1.56) 1.14 (0.83, 1.57) 1.03 (0.74, 1.44) 0.92
a

Adjusted for BMI at blood draw (<25, 25-<25.9, ≥30 kg/m2), age at menarche (≤11, 12, 13, ≥14 years old), alcohol intake (non-drinker, ≤5, 5.01–10, 10.01–15, >15 grams/day), parity/age at first birth (nulliparous, 1 child/<25 years old, 1 child/ ≥25 years old, ≥2 children/<25 years old, ≥2 children/ ≥25 years old), family history of breast cancer (yes/no), history of BBD (yes/no)

When we stratified by menopausal status at diagnosis, significant interactions were detected for α-carotene, β-carotene and total carotenoids (pinteraction=0.03–0.05) (Table 4). While no associations were apparent among women premenopausal at diagnosis, suggested or significant inverse associations between plasma carotenoids and breast cancer risk were observed among women postmenopausal at diagnosis (e.g., lycopene top v. bottom quartile RR (95% CI): premenopausal at diagnosis=1.00 (0.70, 1.42), ptrend=0.99; postmenopausal at diagnosis=0.66 (0.45, 0.96), ptrend=0.02; pheterogeneity=0.03). We further explored these results by examining whether age at blood draw or time between blood draw and diagnosis modified the associations. Associations were similar among women diagnosed <50 and ≥50 (all pheterogeneity ≥0.19). The association between lycopene and risk appeared stronger among women with longer intervals between blood draw and diagnosis (top v. bottom quartile RR (95% CI): <8 years between draw and diagnosis=1.03 (0.71, 1.48), ptrend=0.58; ≥8 years between draw and diagnosis=0.63 (0.45, 0.90), ptrend=0.01; pheterogeneity=0.02), though the associations with other carotenoids did not significantly differ by time to diagnosis (all pheterogeneity ≥0.19). BMI, smoking, and cohort did not modify the relationship of carotenoids and FlOPs with risk (data not shown).

Table 4.

Relative risks (RR) of breast cancer and 95% confidence intervals (CI) according to quartiles of premenopausal carotenoid and FlOP levels, by menopausal status at diagnosisa

N, cases Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend Pheterogeneityb
RR RR (95% CI) RR (95% CI) RR (95% CI)
α-Carotene
Premenopausal at diagnosis 535 1.0 (reference) 1.10 (0.77, 1.58) 0.85 (0.59, 1.23) 1.17 (0.81, 1.68) 0.49 0.05
Postmenopausal at diagnosis 491 1.0 (reference) 0.92 (0.63, 1.35) 0.98 (0.68, 1.42) 0.73 (0.49, 1.06) 0.10
β-Carotene
Premenopausal at diagnosis 535 1.0 (reference) 0.89 (0.62, 1.28) 1.09 (0.75, 1.58) 0.98 (0.68, 1.41) 0.88 0.41
Postmenopausal at diagnosis 492 1.0 (reference) 0.92 (0.63, 1.35) 0.77 (0.52, 1.14) 0.95 (0.63, 1.42) 0.82
β-Cryptoxanthin
Premenopausal at diagnosis 531 1.0 (reference) 0.92 (0.64, 1.33) 1.22 (0.85, 1.76) 0.87 (0.59, 1.27) 0.61 0.40
Postmenopausal at diagnosis 491 1.0 (reference) 0.80 (0.55, 1.15) 0.72 (0.49, 1.05) 0.85 (0.57, 1.26) 0.48
Lutein/Zeaxanthin
Premenopausal at diagnosis 531 1.0 (reference) 1.28 (0.89, 1.83) 1.37 (0.96, 1.97) 1.19 (0.81, 1.75) 0.45 0.13
Postmenopausal at diagnosis 488 1.0 (reference) 0.82 (0.55, 1.22) 0.79 (0.53, 1.17) 0.89 (0.60, 1.33) 0.76
Lycopene
Premenopausal at diagnosis 535 1.0 (reference) 0.82 (0.58, 1.18) 1.13 (0.80, 1.60) 1.00 (0.70, 1.42) 0.65 0.03
Postmenopausal at diagnosis 489 1.0 (reference) 0.92 (0.63, 1.34) 0.73 (0.50, 1.06) 0.66 (0.45, 0.96) 0.02
Total Carotenoids
Premenopausal at diagnosis 526 1.0 (reference) 1.07 (0.75, 1.54) 0.89 (0.62, 1.28) 1.13 (0.78, 1.62) 0.61 0.04
Postmenopausal at diagnosis 482 1.0 (reference) 1.17 (0.81, 1.70) 0.78 (0.52, 1.16) 0.79 (0.53, 1.19) 0.12
a

Adjusted for BMI at blood draw (<25, 25-<25.9, ≥30 kg/m2), age at menarche (≤11, 12, 13, ≥14 years old), alcohol intake (non-drinker, ≤5, 5.01–10, 10.01–15, >15 grams/day), parity/age at first birth (nulliparous, 1 child/<25 years old, 1 child/≥25 years old, ≥2 children/<25 years old, ≥2 children/ ≥25 years old), family history of breast cancer (yes/no), history of benign breast disease (yes/no);

b

P-heterogeneity calculated by evaluating significance of cross-product of ordinal median carotenoid variables and menopausal status using Wald tests

While associations between carotenoids and breast cancer risk did not vary by ER status (all pheterogeneity ≥0.35), FlOP_400 was more strongly inversely associated with risk of ER- tumors (top v. bottom quartile RR (95% CI): ER- tumors=0.55 (0.29, 1.03), ptrend=0.07; ER+ tumors=1.15, (0.79, 1.67), ptrend=0.75 pheterogeneity=0.04) (Suppl. Table 1). When cross-classifying FlOPs and total carotenoid levels, we observed no evidence that women with low carotenoid and high FlOP levels were at increased risk (data not shown).

Genotype frequencies were in Hardy Weinberg equilibrium among controls in all but one SNP (rs17080528); inspection of the cluster plot indicated no evidence of genotyping error and it was included in analyses. In log-additive models, minor alleles of two CAT SNPs were associated with increased breast cancer risk: rs11032686 (per-allele OR=1.31, 95% CI: 1.02, 1.67) and rs7947841 (per-allele OR=1.36, 95% CI: 1.07, 1.74); no other SNPs were associated with risk (Suppl. Table 2). Several SNPs were associated with carotenoids (Suppl. Table 3), including SNPs in the BCMO1 gene, consistent with our previous report.35

Associations between CAT, SOD2, and GPX1 SNPs and breast cancer risk varied by plasma carotenoid level (Table 5). For example, an increasing number of A alleles for CAT SNP rs11032686 appeared to confer an increased risk among women with high levels of β-cryptoxanthin (per-allele OR (95% CI): low β-cryptoxanthin=0.99 (0.65, 1.52); high β-cryptoxanthin=1.98 (1.26, 3.10); pheterogeneity=0.01).

Table 5.

Summary of significant interactions between carotenoid levels (>/< median)a and SNPs in CAT, SOD2, GPX1, MPO and BCMO1 on breast cancer risk in NHSII

Carotenoid Gene rs Number Genotype Minor allele frequency, cases/controls (%) Mean carotenoid level, ug/dLb P-valuec Low carotenoid High carotenoid

Per-minor allele RR (95% CI)d Per-minor allele RR (95% CI) d Pinteraction
β-carotene CAT 208679 AA 88/87 24 0.15 0.76 (0.45, 1.27) 1.07 (0.65, 1.77) 0.04
AG 12/12 21
GG 0.0/0.6 20

GPX1 17080528 CC 44/47 25 0.22 0.79 (0.61, 1.03) 1.10 (0.85, 1.41) 0.04
CT 47/41 23
TT 9/12 23

β-cryptoxanthin CAT 11032686 GG 80/84 10 0.02 0.99 (0.65, 1.52) 1.98 (1.26, 3.10) 0.01
AG 19/16 8.7
AA 0.7/0.5 9.2

CAT 1535721 GG 62/63 10 0.01 0.88 (0.65, 1.19) 1.26 (0.92, 1.71) 0.04
AG 35/33 9.4
AA 3/5 8.4

CAT 7947841 GG 79/84 10 0.03 1.12 (0.74, 1.70) 2.00 (1.28, 3.12) 0.01
AG 20/16 8.8
AA 1/0.6 8.5

Lutein/zeaxanthin SOD2 5746151 CC 88/89 17 0.58 1.69 (1.01, 2.83) 0.92 (0.56, 1.52) 0.02
CT 10/10 17
TT 1/0.5 23

Lycopene SOD2 2758352 GG 64/62 41 0.004 1.10 (0.82, 1.49) 0.74 (0.55, 1.00) 0.02
AG 32/33 44
AA 3/5 48

SOD2 2077560 TT 25/26 46 0.01 1.06 (0.83, 1.35) 1.20 (0.94, 1.54) 0.02
AT 49/52 42
AA 26/22 41

SOD2 2758329 TT 24/26 45 0.03 1.14 (0.89, 1.45) 1.10 (0.85, 1.41) 0.04
CT 51/52 42
CC 25/22 41

SOD2 5746151 CC 88/89 42 0.22 1.51 (0.91, 2.49) 1.01 (0.61, 1.69) 0.02
CT 10/10 44
TT 1/0.5 57

Total carotenoids CAT 1535721 GG 62/63 109 0.06 0.96 (0.70, 1.30) 1.14 (0.85, 1.54) 0.02
AG 35/33 106
AA 3/5 91

CAT 208679 AA 88/87 108 0.07 0.66 (0.40, 1.11) 1.27 (0.75, 2.13) 0.02
AG 12/12 101
GG 0.0/0.6 82

GPX1 17080528 CC 44/47 107 0.60 0.88 (0.67, 1.14) 1.00 (0.78, 1.29) 0.02
CT 47/41 106
TT 9/12 105
a

Carotenoid values dichotomized at median;

b

Carotenoid levels from age-adjusted generalized linear models among controls only;

c

Type III Wald P-value from modeling number of minor alleles continuously;

d

OR (95% CI) calculated from unconditional age-adjusted logistic regression models;

e

P-heterogeneity from likelihood ratio tests with 1 degree of freedom. NOTE: Frequencies may not add up to 100% due to rounding.

DISCUSSION

Overall, we did not find significant associations between premenopausal plasma carotenoid levels and breast cancer risk in this large nested case-control study. However, higher levels of carotenoids during premenopause, particularly lycopene, were suggestively associated with a lower risk of postmenopausal breast cancer. Results did not differ by ER status. While none of the FlOP biomarkers were positively associated with risk, premenopausal levels of FlOP_360 and FlOP_320 were suggestively inversely associated with risk. Lastly, we observed that several SNPs in five genes that influence oxidant and antioxidant status were associated with carotenoid levels, and a small number were suggestively associated with breast cancer risk. Our data additionally suggest that the association between some SNPs and risk are modified by carotenoid levels.

The association between circulating carotenoids and breast cancer risk has been examined previously in several epidemiologic studies, with findings generally suggesting weak or modest protective effects. Although null or largely null findings have been reported in some smaller individual studies,7,9,12 in our pooled analysis, we observed inverse associations between breast cancer risk and α-carotene, β-carotene, lutein/zeaxanthin and total carotenoids (top v. bottom quintile RRs=0.78–0.87). The same carotenoids were also significantly inversely associated with risk in a previous analysis in the NHS that included both postmenopausal and premenopausal participants (RRs=0.64–0.76).10

To date, ours is the first study to specifically investigate premenopausal carotenoids and subsequent breast cancer risk, and our largely null findings may reflect that our study is capturing a different etiologic period than previous analyses, which have assessed exposure later in life. Interestingly, we observed stronger inverse associations among women postmenopausal at diagnosis. This suggests that the effects of carotenoids on risk may differ by hormones, given the stark differences in hormonal milieu by menopausal status. Though we did not observe differences in associations by ER status, stronger inverse associations have been observed with ER- tumors in large pooled studies of dietary3,16 and circulating17 carotenoids, suggesting a stronger association of carotenoids with less hormonally-driven tumors. Alternatively, given their role as antioxidants that may reduce oxidative stress-induced DNA damage,36 the effects of carotenoids may be more pronounced with increasing time since blood collection, reflecting their importance in preventing cancer initiation rather than disease progression. However, the correlation between time since blood collection and postmenopausal status in our data makes it difficult to disentangle these factors.

We found no evidence of a positive association between FlOP levels and overall breast cancer risk; however, we observed suggestive inverse associations with FlOP_360 and FlOP_320. FlOP levels are hypothesized to reflect global levels of oxidation, and have been associated with exposures related to oxidative stress, including cigarette smoking, hypertension, and total cholesterol,37 and with increased risk of coronary heart disease.38,39 Our prior analysis of FlOP measurements and breast cancer risk in the NHS generally suggested no association, though there was evidence that persistently high levels of FlOP_320 were associated with increased risk.21 FlOP measurements quantify interactions between oxidation products with lipids, proteins, carbohydrates, and DNA; it is possible that more specific markers of oxidative stress might have greater relevance to breast cancer etiology, though no associations were observed between prospectively measured urinary markers of lipid peroxidation and breast cancer risk in the Shanghai Women’s Health Study.19,20

Endogenous enzymatic factors may also be involved in defense against oxidative stress. Proteins encoded by CAT, GPX1 and SOD2 may reduce the burden of oxidative stress through neutralization of ROS into compounds with less carcinogenic potential, while the MPO enzyme contributes to oxidative stress through formation of oxidants. Previous findings suggest that the effect of GPX1 SNP rs4880 on breast,40 cervical41 and prostate cancer42 risk may be modified by antioxidant status. We did not observe interactions between rs4880 and carotenoids on breast cancer risk, but found interactions with four other GPX1 SNPs. We additionally noted interactions between carotenoids, several CAT SNPs and breast cancer risk, and an increased risk with two other CAT SNPs. At least one functional polymorphism in the promoter region of this gene (rs1001179) has been shown to decrease catalase activity,4345 which could hypothetically affect cancer risk. However, results from epidemiologic studies have been inconsistent,46,47 and our results did not indicate evidence of any significant association with this SNP.

BCMO1 plays a central role in the conversion of provitamin A carotenoids to retinal, and activity of this protein is reduced among women with copies of the rs6564851 minor allele.48 Consistent with previous findings from the NHS and other studies,35,4850 a positive association between the G allele of rs6564851 have been observed with α-carotene and β-carotene levels, and an inverse association with lutein/zeaxanthin.35,50 Positive associations between rs12934922 variants and plasma levels of some carotenoids have also been reported,35,49 though we did not observe significant associations with this SNP. We also observed several significant associations between SNPs in CAT, GPX, SOD2 and MPO and carotenoids; to our knowledge, these associations have not previously been studied.

There are several limitations to our study. First, carotenoids and FlOPs were assessed at a single time point. However, among postmenopausal women in the NHS, plasma carotenoids had good reproducibility over a three-year period (intraclass correlation (ICC): 0.73–0.80),51 suggesting that one measurement adequately represents longer-term exposure status. FlOP measurements are fairly representative, with comparable ICCs of 0.44–0.70,38 although 10-year ICCs were notably lower (0.14–0.30).21 Additionally, we performed a large number of statistical tests, and at least some of significant associations may be due to chance. Because many of these associations had not been previously evaluated, we opted not to adjust for multiple testing; however, these results should be viewed as exploratory and interpreted with caution. Lastly, we cannot rule out the possibility of unmeasured confounding, despite adjusting our analyses for known and suspected confounders.

Overall, we did not observe significant inverse associations between premenopausal levels of circulating carotenoid and subsequent breast cancer risk in this large nested case-control study. Additionally, we did not observe positive associations with circulating markers of oxidative stress, but instead found suggestive inverse associations with two FlOP measurements. Evidence of inverse associations between some carotenoids and risk appeared limited to postmenopausal breast cancer, suggesting some interaction between these exposures and hormonal factors. Although we conducted many tests, our results suggest that genetic variation in CAT, GPX, SOD2 and MPO genes may impact circulating carotenoid levels and potentially breast cancer risk. Further work is needed to elucidate the complex roles of oxidant and antioxidant factors in breast carcinogenesis.

Supplementary Material

10549_2015_3391_MOESM1_ESM

Acknowledgments

Funding/support: This study was supported in part by R01 CA050385 (Walter Willett, PI) and UM1 CA176726 (Willett, PI). This project was additionally supported in part by UM1 CA186107, P01 CA87969, R01 CA49449 and R01 CA67262. Julia Sisti was supported by training grants R25 CA098566 and T32 CA900137.

We would like to thank the participants and staff of the Nurses Health Study and Nurses’ Health Study II for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

Footnotes

Disclosures of potential conflicts of interest: None

References

  • 1.Van Gils CH, et al. Consumption of vegetables and fruits and risk of breast cancer. JAMA J Am Med Assoc. 2005;293:183–193. doi: 10.1001/jama.293.2.183. [DOI] [PubMed] [Google Scholar]
  • 2.Lissowska J, et al. Intake of fruits, and vegetables in relation to breast cancer risk by hormone receptor status. Breast Cancer Res Treat. 2008;107:113–117. doi: 10.1007/s10549-007-9524-9. [DOI] [PubMed] [Google Scholar]
  • 3.Jung S, et al. Fruit and vegetable intake and risk of breast cancer by hormone receptor status. J Natl Cancer Inst. 2013;105:219–236. doi: 10.1093/jnci/djs635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Smith-Warner SA, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA J Am Med Assoc. 2001;285:769–776. doi: 10.1001/jama.285.6.769. [DOI] [PubMed] [Google Scholar]
  • 5.Aune D, et al. Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat. 2012;134:479–493. doi: 10.1007/s10549-012-2118-1. [DOI] [PubMed] [Google Scholar]
  • 6.Toniolo P, et al. Serum carotenoids and breast cancer. Am J Epidemiol. 2001;153:1142–1147. doi: 10.1093/aje/153.12.1142. [DOI] [PubMed] [Google Scholar]
  • 7.Dorjgochoo T, et al. Plasma carotenoids, tocopherols, retinol and breast cancer risk: results from the Shanghai Women Health Study (SWHS) Breast Cancer Res Treat. 2009;117:381–389. doi: 10.1007/s10549-008-0270-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Kabat GC, et al. Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. Am J Clin Nutr. 2009;90:162–169. doi: 10.3945/ajcn.2009.27568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Epplein M, et al. Plasma carotenoids, retinol, and tocopherols and postmenopausal breast cancer risk in the Multiethnic Cohort Study: a nested case-control study. Breast Cancer Res BCR. 2009;11:R49. doi: 10.1186/bcr2338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Tamimi RM, et al. Plasma carotenoids, retinol, and tocopherols and risk of breast cancer. Am J Epidemiol. 2005;161:153–160. doi: 10.1093/aje/kwi030. [DOI] [PubMed] [Google Scholar]
  • 11.Sato R, et al. Prospective study of carotenoids, tocopherols, and retinoid concentrations and the risk of breast cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2002;11:451–457. [PubMed] [Google Scholar]
  • 12.Maillard V, et al. Serum carotenoid, tocopherol and retinol concentrations and breast cancer risk in the E3N-EPIC study. Int J Cancer J Int Cancer. 2010;127:1188–1196. doi: 10.1002/ijc.25138. [DOI] [PubMed] [Google Scholar]
  • 13.Aune D, et al. Dietary compared with blood concentrations of carotenoids and breast cancer risk: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2012;96:356–373. doi: 10.3945/ajcn.112.034165. [DOI] [PubMed] [Google Scholar]
  • 14.Mignone LI, et al. Dietary carotenoids and the risk of invasive breast cancer. Int J Cancer J Int Cancer. 2009;124:2929–2937. doi: 10.1002/ijc.24334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Nagel G, et al. Dietary beta-carotene, vitamin C and E intake and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Breast Cancer Res Treat. 2010;119:753–765. doi: 10.1007/s10549-009-0444-8. [DOI] [PubMed] [Google Scholar]
  • 16.Zhang X, et al. Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies. Am J Clin Nutr. 2012;95:713–725. doi: 10.3945/ajcn.111.014415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Eliassen AH, et al. Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies. J Natl Cancer Inst. 2012;104:1905–1916. doi: 10.1093/jnci/djs461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 2004;44:239–267. doi: 10.1146/annurev.pharmtox.44.101802.121851. [DOI] [PubMed] [Google Scholar]
  • 19.Dai Q, et al. Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women’s Health Study. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:2482–2488. doi: 10.1200/JCO.2008.19.7970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lee KH, et al. Breast cancer and urinary biomarkers of polycyclic aromatic hydrocarbon and oxidative stress in the Shanghai Women’s Health Study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2010;19:877–883. doi: 10.1158/1055-9965.EPI-09-1098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Fortner RT, Tworoger SS, Wu T, Eliassen AH. Plasma florescent oxidation products and breast cancer risk: repeated measures in the Nurses’ Health Study. Breast Cancer Res Treat. 2013;141:307–316. doi: 10.1007/s10549-013-2673-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hankinson SE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst. 1995;87:1297–1302. doi: 10.1093/jnci/87.17.1297. [DOI] [PubMed] [Google Scholar]
  • 23.Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res. 2006;66:2476–2482. doi: 10.1158/0008-5472.CAN-05-3369. [DOI] [PubMed] [Google Scholar]
  • 24.Eliassen AH, et al. Plasma carotenoids and risk of breast cancer over 20 years of follow-up. Am J Clinincal Nutr. doi: 10.3945/ajcn.114.105080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.El-Sohemy A, et al. Individual carotenoid concentrations in adipose tissue and plasma as biomarkers of dietary intake. Am J Clin Nutr. 2002;76:172–179. doi: 10.1093/ajcn/76.1.172. [DOI] [PubMed] [Google Scholar]
  • 26.Wu T, Rifai N, Roberts LJ, 2nd, Willett WC, Rimm EB. Stability of measurements of biomarkers of oxidative stress in blood over 36 hours. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2004;13:1399–1402. [PubMed] [Google Scholar]
  • 27.Rosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol. 2008;167:653–666. doi: 10.1093/aje/kwm348. [DOI] [PubMed] [Google Scholar]
  • 28.De Bakker PIW, et al. Efficiency and power in genetic association studies. Nat Genet. 2005;37:1217–1223. doi: 10.1038/ng1669. [DOI] [PubMed] [Google Scholar]
  • 29.Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinforma Oxf Engl. 2005;21:263–265. doi: 10.1093/bioinformatics/bth457. [DOI] [PubMed] [Google Scholar]
  • 30.Ambrosone CB. Oxidants and antioxidants in breast cancer. Antioxid Redox Signal. 2000;2:903–917. doi: 10.1089/ars.2000.2.4-903. [DOI] [PubMed] [Google Scholar]
  • 31.Lietz G, Lange J, Rimbach G. Molecular and dietary regulation of beta,beta-carotene 15,15’-monooxygenase 1 (BCMO1) Arch Biochem Biophys. 2010;502:8–16. doi: 10.1016/j.abb.2010.06.032. [DOI] [PubMed] [Google Scholar]
  • 32.Hendrickson SJ, et al. Plasma carotenoid- and retinol-weighted multi-SNP scores and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2013;22:927–936. doi: 10.1158/1055-9965.EPI-13-0017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Rosner B. Percentage Points for a Generalized ESD Many-Outlier Procedure. Technometrics. 1983;25:165–172. [Google Scholar]
  • 34.Marshall RJ, Chisholm EM. Hypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancer. Stat Med. 1985;4:337–344. doi: 10.1002/sim.4780040313. [DOI] [PubMed] [Google Scholar]
  • 35.Hendrickson SJ, et al. β-Carotene 15,15’-monooxygenase 1 single nucleotide polymorphisms in relation to plasma carotenoid and retinol concentrations in women of European descent. Am J Clin Nutr. 2012;96:1379–1389. doi: 10.3945/ajcn.112.034934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Frei B. Reactive oxygen species and antioxidant vitamins: mechanisms of action. Am J Med. 1994;97:5S–13S. doi: 10.1016/0002-9343(94)90292-5. discussion 22S–28S. [DOI] [PubMed] [Google Scholar]
  • 37.Wu T, Willett WC, Rifai N, Rimm EB. Plasma fluorescent oxidation products as potential markers of oxidative stress for epidemiologic studies. Am J Epidemiol. 2007;166:552–560. doi: 10.1093/aje/kwm119. [DOI] [PubMed] [Google Scholar]
  • 38.Jensen MK, et al. Fluorescent oxidation products and risk of coronary heart disease: a prospective study in women. J Am Heart Assoc. 2013;2:e000195. doi: 10.1161/JAHA.113.000195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Wu T, Rifai N, Willett WC, Rimm EB. Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men. Am J Epidemiol. 2007;166:544–551. doi: 10.1093/aje/kwm120. [DOI] [PubMed] [Google Scholar]
  • 40.Wang S, et al. Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk - A meta-analysis. Eur J Cancer Oxf Engl 1990. 2009;45:2874–2881. doi: 10.1016/j.ejca.2009.04.024. [DOI] [PubMed] [Google Scholar]
  • 41.Tong SY, et al. Functional polymorphism in manganese superoxide dismutase and antioxidant status: their interactions on the risk of cervical intraepithelial neoplasia and cervical cancer. Gynecol Oncol. 2009;115:272–276. doi: 10.1016/j.ygyno.2009.07.032. [DOI] [PubMed] [Google Scholar]
  • 42.Mikhak B, et al. Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis. 2008;29:2335–2340. doi: 10.1093/carcin/bgn212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ahn J, et al. Associations between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2006;15:1217–1222. doi: 10.1158/1055-9965.EPI-06-0104. [DOI] [PubMed] [Google Scholar]
  • 44.Nadif R, et al. Association of CAT polymorphisms with catalase activity and exposure to environmental oxidative stimuli. Free Radic Res. 2005;39:1345–1350. doi: 10.1080/10715760500306711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Bastaki M, et al. Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans. Pharmacogenet Genomics. 2006;16:279–286. doi: 10.1097/01.fpc.0000199498.08725.9c. [DOI] [PubMed] [Google Scholar]
  • 46.Ahn J, et al. Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement use. Am J Epidemiol. 2005;162:943–952. doi: 10.1093/aje/kwi306. [DOI] [PubMed] [Google Scholar]
  • 47.Quick SK, et al. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2008;17:1082–1087. doi: 10.1158/1055-9965.EPI-07-2755. [DOI] [PubMed] [Google Scholar]
  • 48.Lietz G, Oxley A, Leung W, Hesketh J. Single nucleotide polymorphisms upstream from the β-carotene 15,15’-monoxygenase gene influence provitamin A conversion efficiency in female volunteers. J Nutr. 2012;142:161S–5S. doi: 10.3945/jn.111.140756. [DOI] [PubMed] [Google Scholar]
  • 49.Leung WC, et al. Two common single nucleotide polymorphisms in the gene encoding beta-carotene 15,15’-monoxygenase alter beta-carotene metabolism in female volunteers. FASEB J Off Publ Fed Am Soc Exp Biol. 2009;23:1041–1053. doi: 10.1096/fj.08-121962. [DOI] [PubMed] [Google Scholar]
  • 50.Ferrucci L, et al. Common variation in the beta-carotene 15,15’-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet. 2009;84:123–133. doi: 10.1016/j.ajhg.2008.12.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Kotsopoulos J, et al. Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses’ Health Studies. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2010;19:938–946. doi: 10.1158/1055-9965.EPI-09-1318. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

10549_2015_3391_MOESM1_ESM

RESOURCES